Expert Commentary

Top 3 things I learned at the NAMS 2016 annual meeting

Publish date: November 9, 2016
By
Steven R. Goldstein, MD, NCMP, CCD
Author and Disclosure Information

Dr. Goldstein discusses CV risk assessment in women; calcium and Vitamin D supplementation; gender disparities in diseases and drug dosing; the NAMS 2016 HT position statement; and appropriate surgical treatment for ovarian masses

 

Recommended Reading

Liletta gets a new inserter: Steps for successful placement
MDedge ObGyn
CDC: Seven cases of multidrug resistant C. auris have occurred in United States
MDedge ObGyn
Expert tips for working with aspiring LGBT parents
MDedge ObGyn
Nonsurgical biomarkers show potential in chronic endometriosis
MDedge ObGyn
Meaningful use: CMS extends 90-day reporting period to 2016, 2017
MDedge ObGyn
Natural orifice sacral colpopexy
MDedge ObGyn
Another Zika vaccine heads to Phase I trials
MDedge ObGyn
Giving women HIV self-tests increases male partner testing
MDedge ObGyn
FDA addresses unmet need in drug development guidance for female sexual dysfunction
MDedge ObGyn
What will the Trump administration mean for medicine?
MDedge ObGyn